Notices. Notice of application
328 words·~1 min read·
/register/2016/02/12/2016-02863A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 7020-02-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-392] Bulk Manufacturer of Controlled Substances Application: Noramco, Inc. ACTION: Notice of application. DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before April 12, 2016. ADDRESSES: Written comments should be sent to:
Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on August 4, 2015, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance Schedule Gamma Hydroxybutyric Acid
(2010)I Codeine-N-oxide
(9053)I Dihydromorphine
(9145)I Morphine-N-oxide
(9307)I Amphetamine
(1100)II Methylphenidate
(1724)II Codeine
(9050)II Dihydrocodeine
(9120)II Oxycodone
(9143)II Hydromorphone
(9150)II Hydrocodone
(9193)II Morphine
(9300)II Oripavine
(9330)II Thebaine
(9333)II Opium tincture
(9630)II Oxymorphone
(9652)II Noroxymorphone
(9668)II Alfentanil
(9737)II Sufentanil
(9740)II Carfentanil
(9743)II Tapentadol
(9780)II Fentanyl
(9801)II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Dated: January 27, 2016. Louis J. Milione, Deputy Assistant Administrator. [FR Doc. 2016-02863 Filed 2-11-16; 8:45 am]
Connectionstraces to 2
2 references not yet in our index
- 21 CFR 1301
- 28 CFR 0
Citation graph
cites case law
Cites 4Cited by 0 across 0 sources